Avid Bioservices Competitors

Avid Bioservices (NASDAQ:CDMOP) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Avid Bioservices and AbCellera Biologics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Avid Bioservices and AbCellera Biologics' top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Avid Bioservices and AbCellera Biologics, as reported by MarketBeat.com.

AbCellera Biologics has a consensus target price of $52.80, suggesting a potential upside of 82.07%. Given AbCellera Biologics' higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Avid Bioservices.

Summary

AbCellera Biologics beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Avid Bioservices (NASDAQ:CDMOP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Sana Biotechnology and Avid Bioservices, as provided by MarketBeat.

Sana Biotechnology presently has a consensus target price of $40.00, suggesting a potential upside of 57.67%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Avid Bioservices.

Profitability

This table compares Sana Biotechnology and Avid Bioservices' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Sana Biotechnology and Avid Bioservices' revenue, earnings per share and valuation.

Summary

Sana Biotechnology beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and Avid Bioservices (NASDAQ:CDMOP) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Abcam and Avid Bioservices, as provided by MarketBeat.com.

Abcam presently has a consensus price target of $22.00, indicating a potential upside of 12.02%. Given Abcam's higher probable upside, analysts clearly believe Abcam is more favorable than Avid Bioservices.

Profitability

This table compares Abcam and Avid Bioservices' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Abcam and Avid Bioservices' top-line revenue, earnings per share and valuation.

Summary

Abcam beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Avid Bioservices (NASDAQ:CDMOP) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares Seer and Avid Bioservices' revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of recent ratings for Seer and Avid Bioservices, as reported by MarketBeat.

Seer presently has a consensus price target of $68.00, indicating a potential upside of 25.79%. Given Seer's higher probable upside, research analysts plainly believe Seer is more favorable than Avid Bioservices.

Profitability

This table compares Seer and Avid Bioservices' net margins, return on equity and return on assets.

Summary

Seer beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMOP) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Profitability

This table compares Avid Bioservices and Nuvation Bio's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Avid Bioservices and Nuvation Bio, as reported by MarketBeat.

Nuvation Bio has a consensus target price of $17.40, suggesting a potential upside of 46.10%. Given Nuvation Bio's higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Avid Bioservices.

Valuation & Earnings

This table compares Avid Bioservices and Nuvation Bio's gross revenue, earnings per share and valuation.

Summary

Nuvation Bio beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMOP) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Avid Bioservices and ImmunityBio's top-line revenue, earnings per share and valuation.

Profitability

This table compares Avid Bioservices and ImmunityBio's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Avid Bioservices and ImmunityBio, as reported by MarketBeat.

ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 36.54%. Given ImmunityBio's higher probable upside, analysts clearly believe ImmunityBio is more favorable than Avid Bioservices.

Summary

ImmunityBio beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.